American Well Corporation (AMWL) came out with a quarterly loss of $1.74 per share versus the Zacks Consensus Estimate of a loss of $1.83. This compares to a loss of $2.87 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.92%. A quarter ago, it was expected that this company would post a loss of $1.84 per share when it actually produced a loss of $1.24, delivering a surprise of +32.61%.Over the last four quarters, the company ...

Clover Health Investments, Corp. (CLOV) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.02. This compares to a loss of $0.02 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -100.00%. A quarter ago, it was expected that this company would post earnings of $0.03 per share when it actually produced earnings of $0.03, delivering no surprise.Over the last four quarters, the company has sur ...

Tempus AI (TEM) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +31.25%. A quarter ago, it was expected that this health care technology company would post a loss of $0.23 per share when it actually produced a loss of $0.22, delivering a surprise of +4.35%.Over the last four quarters, the c ...

Investors with an interest in Medical Info Systems stocks have likely encountered both Omnicell (OMCL) and Hims & Hers Health, Inc. (HIMS) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight ...

季度业绩表现 - 季度每股亏损为0.06美元 显著优于市场预期的每股亏损0.36美元 与去年同期每股亏损1.26美元相比大幅收窄 [1] - 本季度盈利超出预期83.33% 上一季度盈利超出预期39.62% 在过去四个季度中有三次超过每股收益预期 [1] - 季度营收达到1.9288亿美元 超出市场共识预期4.97% 较去年同期的1.4754亿美元增长30.7% 在过去四个季度中均超过营收预期 [2] 市场表现与展望 - 公司股价自年初以来累计上涨约105.5% 远超同期标普500指数17.2%的涨幅 [3] - 当前市场对下一季度的共识每股收益预期为亏损0.09美元 营收预期为1.9615亿美元 对本财年的共识每股收益预期为亏损1.71美元 营收预期为7.2526亿美元 [7] - 盈利预测修正趋势在财报发布前表现不一 当前Zacks评级为第3级（持有）预计短期内表现与市场同步 [6] 行业比较 - 公司所属的医疗信息系统行业在Zacks行业排名中位列前21% 研究显示排名前50%的行业表现优于后50%的行业超过两倍 [8] - 同业公司Biotricity Inc 尚未公布截至2025年9月的季度业绩 市场预期其季度每股亏损为0.08美元 较去年同期恶化14.3% 营收预期为390万美元 同比增长19.3% [9]

核心观点 - 华尔街预期10x Genomics在2025年第三季度将实现每股亏损收窄，但营收同比下降，实际业绩与预期的对比可能影响股价短期走势 [1] - 公司的盈利意外指针和Zacks排名组合显示，其大概率将超出每股收益预期 [12] - 公司过往四个季度中有三个季度每股收益超出预期，最近一个季度实现惊人增长 [13][14] 财务业绩预期 - 预计季度每股亏损为0.27美元，同比改善10% [3] - 预计季度营收为1.4239亿美元，同比下降6.1% [3] - 过去30天内，季度每股收益共识预期被上调了1.46% [4] 盈利预测模型分析 - Zacks盈利ESP模型通过对比“最精确预期”与“共识预期”来预测业绩意外 [7][8] - 正的盈利ESP理论上预示着实际收益可能高于共识预期，该模型对正ESP读数的预测能力显著 [9] - 当正盈利ESP与Zacks排名第1、2或3级结合时，预测股价产生正意外的概率接近70% [10] - 10x Genomics的盈利ESP为+11.39%，Zacks排名为第1级，表明其很可能超出每股收益预期 [12] 同行业公司对比 - 同属医疗信息系统行业的Nyxoah SA预计季度每股亏损0.61美元，同比恶化10.9% [18] - Nyxoah预计季度营收为195万美元，同比增长40.3% [18] - Nyxoah的盈利ESP为+19.67%，但其Zacks排名为第4级，难以预测其是否会超出每股收益预期 [19] - Nyxoah在过去四个季度中仅一次超出每股收益预期 [19]

Omnicell (OMCL) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.56 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +41.67%. A quarter ago, it was expected that this Omnicell Inc. would post earnings of $0.31 per share when it actually produced earnings of $0.45, delivering a surprise of +45.16%.Over the last four quarters, the company ...

Key Takeaways HIMS is set to report Q3 results with EPS estimated to be 9 cents and revenues of $583.7 million.HIMS' new hormonal health offerings and AI enhancements aim to expand reach and lift user engagement in Q3.HIMS continues to scale via women's health launches and global digital expansion, driving long-term growth.Hims & Hers Health, Inc. (HIMS) is scheduled to report third-quarter 2025 results on Nov. 3, after the closing bell.In the last reported quarter, the company’s earnings per share (EPS) of ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Doximity (DOCS) , which belongs to the Zacks Medical Info Systems industry.This medical social networking site has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 28.43%.For the last reported quarter, Doximity came out with earnings of $0.36 per share ver ...

核心观点 - 华尔街预计Nyxoah SA在2025年第三季度营收增长但每股亏损同比扩大，实际业绩与预期的对比将影响股价短期走势 [1] - 尽管Nyxoah的盈利意外指针为正，但由于其Zacks评级较低，难以确定其能否超出盈利预期 [12][17] - 行业同类公司Hims & Hers Health也面临类似情况，难以确定其能否超出盈利预期 [18][20] Nyxoah SA 业绩预期 - 预计季度每股亏损为0.61美元，同比恶化10.9% [3] - 预计季度营收为195万美元，同比增长40.3% [3] - 过去30天内，季度共识每股亏损预期被下调了6.1% [4] - 最准确估计高于共识估计，盈利意外指针为+19.67%，表明分析师近期转向看好 [12] Nyxoah SA 历史表现 - 上一季度实际每股亏损0.63美元，低于预期的0.62美元，意外偏差为-1.61% [13] - 过去四个季度中，仅有一次业绩超出每股收益预期 [14] Zacks 盈利预测模型 - 盈利意外指针通过比较最准确估计与共识估计来预测实际业绩偏离方向 [8][9] - 当盈利意外指针为正且Zacks评级为1至3级时，预测股价上涨的准确率接近70% [10] - 盈利意外指针为负或Zacks评级为4至5级时，难以预测业绩是否会低于预期 [11] 行业比较：Hims & Hers Health, Inc - 预计季度每股收益为0.09美元，同比增长50% [18] - 预计季度营收为5.8368亿美元，同比增长45.4% [19] - 过去30天内共识每股收益预期被下调4%，盈利意外指针为-12.79% [19] - 结合其Zacks评级第3级，难以预测其将超出盈利预期，过去四个季度仅一次超出预期 [20]